Nature Communications (Jan 2020)
Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary
- Sarah H. Kim,
- Arnaud Da Cruz Paula,
- Thais Basili,
- Higinio Dopeso,
- Rui Bi,
- Fresia Pareja,
- Edaise M. da Silva,
- Rodrigo Gularte-Mérida,
- Zhen Sun,
- Sho Fujisawa,
- Caitlin G. Smith,
- Lorenzo Ferrando,
- Ana Paula Martins Sebastião,
- Yonina Bykov,
- Anqi Li,
- Catarina Silveira,
- Charles W. Ashley,
- Anthe Stylianou,
- Pier Selenica,
- Wesley R. Samore,
- Achim A. Jungbluth,
- Dmitriy Zamarin,
- Nadeem R. Abu-Rustum,
- Kristian Helin,
- Robert A. Soslow,
- Jorge S. Reis-Filho,
- Esther Oliva,
- Britta Weigelt
Affiliations
- Sarah H. Kim
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Arnaud Da Cruz Paula
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Thais Basili
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Higinio Dopeso
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Rui Bi
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Fresia Pareja
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Edaise M. da Silva
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Rodrigo Gularte-Mérida
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Zhen Sun
- Cell Biology Program and Center for Epigenetics, Memorial Sloan Kettering Cancer Center
- Sho Fujisawa
- Molecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center
- Caitlin G. Smith
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Lorenzo Ferrando
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Ana Paula Martins Sebastião
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Yonina Bykov
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Anqi Li
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Catarina Silveira
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Charles W. Ashley
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Anthe Stylianou
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Pier Selenica
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Wesley R. Samore
- Department of Pathology, Massachusetts General Hospital, Harvard Medical School
- Achim A. Jungbluth
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Dmitriy Zamarin
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Nadeem R. Abu-Rustum
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Kristian Helin
- Cell Biology Program and Center for Epigenetics, Memorial Sloan Kettering Cancer Center
- Robert A. Soslow
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Jorge S. Reis-Filho
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Esther Oliva
- Department of Pathology, Massachusetts General Hospital, Harvard Medical School
- Britta Weigelt
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- DOI
- https://doi.org/10.1038/s41467-019-13806-x
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 16
Abstract
Little is known about the genetics of sclerosing stromal tumor of the ovary, a rare type of sex cord-stromal tumor. Here, the authors use sequencing strategies to show that in a cohort of 26 tumor samples 65% carry a FHL2-GLI2 fusion gene and demonstrate in vitro that the fusion gene has oncogenic properties.
